Stay updated with breaking news from Michael Sofia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WARMINSTER, Pa., May 02, 2024 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with...
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript August 3, 2023 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $0.12. Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Q2 Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. […]
WARMINSTER, Pa., May 31, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target... | May 31, 2023
WARMINSTER, Pa., May 09, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target... | May 9, 2023
Science's COVID-19 reporting is supported by the Heising-Simons Foundation ILLUSTRATION: STEPHAN SCHMITZ/FOLIO ART In March 2020, as the scope of the COVID-19 pandemic was coming into view, Jen Nwankwo and colleagues turned a pair of artificial intelligence (AI) tools against SARS-CoV-2. One newly developed AI program, called SUEDE, digitally screens all known druglike compounds for likely activity against biomolecules thought to be involved in disease. The other, BAGEL, predicts how to build inhibitors to known targets. The two programs searched for compounds able to block human enzymes that...